Tyra Biosciences, Inc.TYRA

Tyra Biosciences’ 10-Q for the quarter ended 31 March 2026 shows a company that can raise money faster than it can turn it into product sales: net loss of $39.3 million, operating loss of $42.0 million, and a cash burn from operations of $32.6 million, all against a still-modest $85.0 million of cash and equivalents. The firm sold 4.7 million shares in the quarter under a $150 million sales agreement and banked $147.9 million after expenses, yet the clinical engine continues to suck oxygen at $33.5 million of R&D per three-month period. (source: TYRA SEC EDGAR 10-Q, 2026-05-13, https://www.sec.gov/Archives/edgar/data/1863127/000119312526220645/tyra-20260331.htm)

Tyra describes itself as a clinical-stage biopharmaceutical company focused on correcting fibroblast growth factor receptor dysregulation, which in plain English means it is still in the trial-and-error phase of turning biology into revenue. Its lead programme, TYRA-200, is being tested in the SURF201 Phase 1 study for previously treated and resistant FGFR2-positive cholangiocarcinoma and other advanced solid tumours. The company’s own patient pages admit it has no expanded access programme today, and clinical-trial queries are directed to clinicaltrials.gov. Until a drug is approved and reimbursed, Tyra’s business model remains a capital-markets operation with a side of Phase 1 science. (source: Pipeline & Targets, https://tyra.bio/pipeline/; Patients, https://tyra.bio/patients/)

The balance sheet looks structurally solvent but operationally thirsty: total assets of $412.0 million against liabilities of $24.5 million, with shareholders’ equity of $387.6 million. Cash flow from operations was negative $32.6 million in the quarter, while capex was a rounding error at $88,000. Diluted EPS came in at a $0.64 loss on 61.7 million weighted average shares, and the 10-Q flags that the company may continue to sell shares under its sales agreement-an arrangement that keeps the lights on but steadily dilutes existing holders. (source: TYRA SEC EDGAR 10-Q, 2026-05-13, https://www.sec.gov/Archives/edgar/data/1863127/000119312526220645/tyra-20260331.htm)

Tyra’s market story is ultimately a capital-markets narrative until the clinical data improve. The stock trades on hope, liquidity, and the periodic drumbeat of share sales rather than on any approved product revenue. Investors who want a chart view can follow the ordinary share on the primary listing venue via standard market data feeds; Tyra itself points to its own minimal web footprint for anything beyond pipeline promise. The filing trail is available on SEC EDGAR, and the company’s 144/A filings show insider and director activity, but none of these documents substitute for regulatory approval or reimbursement contracts. (source: TYRA SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1863127; SEC submissions JSON, https://data.sec.gov/submissions/CIK0001863127.json)

What changed this week: no new clinical data were released; the operating burn and cash proceeds from share sales remain the dominant story. What remains unproven: whether TYRA-200 can deliver meaningful clinical benefit in cholangiocarcinoma or any other indication, and whether the firm can graduate from a capital-raising venture to a revenue-generating biotech. The next catalyst is the next interim or final readout from SURF201, plus any updates on reimbursement discussions once a pivotal readout is available. The company’s website and clinicaltrials.gov are the primary channels for such announcements. (source: Pipeline & Targets, https://tyra.bio/pipeline/; Patients, https://tyra.bio/patients/)

Tyra’s market identity is therefore a hybrid: a cash-guzzling science project with a disciplined capital-markets strategy, dressed in the language of patient-first oncology. Until the Phase 1 study produces data that investors can price, the stock’s volatility is tied less to tumour response rates and more to the rhythm of share sales and the willingness of public markets to fund the burn. The filing trail is transparent; the clinical outcome trail is not. (source: TYRA SEC EDGAR 10-Q, 2026-05-13, https://www.sec.gov/Archives/edgar/data/1863127/000119312526220645/tyra-20260331.htm)